25th -26th Febuary 2021

3rd Edition MarketsandMarkets Next Gen Microbiome and Probiotics- Virtual Conference (Time Zone- Eastern Standard Time (EST))

Witness the significant development of microbiome, probiotics and prebiotics research alongside their applications relating to difficulties like therapeutic information understanding, speculation and administrative obstacles looked by the experts. The convergence between developing innovation and disclosure with the setting of consumer intrigue. Recognize the non-distinguished dysbiosis, to find the expected territories under examination for interests in Gut and Skin microbiome and its part as an indicative instrument of drug revelation. 

Connect with biotech, pharma, academicians and investors at 3rd Edition Next Gen Microbiome and Probiotics- Virtual Conference, February 2021 discussing the most ingenious research and technological advances. This online conference will hold discussions on the nutraceutical and consumer approaches along with Microbiome as a science and its clinical application. Key sessions on R& D to commercialization- how to effectively translate research into commercialization along with overcoming microbiome research and probiotics product development challenges.

WHAT TO EXPECT
Key Highlights
  • Microbial Innovations
  • Microbiome as a science and its clinical applications- skin, gut & women’s health
  • Overcoming microbiome research and probiotics product development challenges Pediatrics and infant health
  • Live Probiotic Technology
  • Strain Identification
  • Fecal Microbiota & Engineered Microbiome
  • R& D to commercialization- effectively translating research into commercialization
Who Should Attend?

Medical Directors, Principal Investigators, Methodologists, and other clinical research professionals from pharmaceuticals, nutraceuticals and therapeutics-based organizations from the departments of:

  • Microbiome discovery
  • Department of Biochemistry and Immunology
  • Microbiome science
  • Microbiology
  • Biological Science
  • Gut Biology
  • Human microbiome
  • Drug discovery
  • Therapeutics
  • Immunotherapy 
CONFERENCE AGENDA
MICROBIOME DISCOVERIES
R&D TO COMMERCIALIZATION- EFFECTIVELY TRANSLATING RESEARCH INTO COMMERCIALIZATION
CONFERENCE SPEAKERS
Speakers
 Maya Ivanjesku

Maya Ivanjesku

Chief Scientific Officer
Dakota Biotech

Maya Ivanjesku

Chief Scientific Officer
Dakota Biotech
Bruce Topping

Bruce Topping

Director of Product Development
HempFusion, Inc.

Bruce Topping

Director of Product Development
HempFusion, Inc.
 Emily Stein

Emily Stein

CEO
Primal Health Inc.

Emily Stein

CEO
Primal Health Inc.
Todd Krueger

Todd Krueger

President & CEO
AOBiome

Todd Krueger

President & CEO
AOBiome
 Allison Krebs-Bensch

Allison Krebs-Bensch

CEO
US Pharmaceutical Corporation

Allison Krebs-Bensch

CEO
US Pharmaceutical Corporation
 Julie Schwedock

Julie Schwedock

Associate Director, Microbial Development Team
Takeda Pharmaceuticals

Julie Schwedock

Associate Director, Microbial Development Team
Takeda Pharmaceuticals
 Julius Goepp

Julius Goepp

Founder, CEO
Scaled Microbiomics

Julius Goepp

Founder, CEO
Scaled Microbiomics
Linda Krebs

Linda Krebs

Cofounder, COO
Bebe and Bella

Linda Krebs

Cofounder, COO
Bebe and Bella
SPONSORS
Gold
example-image

vermicon AG

Silver
example-image

Biome Research - HempFusion

Sponsors & Exhibitors
example-image

Intertek

example-image

Voisin Consulting Life Sciences

example-image

Biose Industrie

PARTNERS
Supporting Association
Medicon Valley Alliance

Medicon Valley Alliance

Media Partners
example-image

Microbiome Post

example-image

Bacteriophage.news

PAST EVENT GALLERY